The effect of epidermal growth factor (EGF) conjugated with low-molecular-weight protamine (LMWP) on wound healing of the skin.

This study was designed to develop a skin permeable recombinant low-molecular-weight protamine (LMWP) conjugated epidermal growth factor (EGF) (rLMWP-EGF) by linking a highly positive charged LMWP to the N-terminal of EGF through genetic recombination. We evaluated its biological activity, skin permeability, and wound healing efficacy in vivo. The cDNA for rLMWP-EGF was prepared by serial polymerase chain reaction for encoding amino acids of LMWP to the vector for EGF. After expression and purification, recombinant EGF site-specifically conjugated with LMWP was obtained. The in vitro cell proliferation activity was well preserved after LMWP conjugation and was comparable to that of rEGF. rLMWP-EGF showed markedly improved permeability through the three-dimensional artificial human skin constructs, and the cumulative permeation of rLMWP-EGF across the excised mouse skin was about 11 times higher than that of rEGF. Topically applied rLMWP-EGF significantly accelerated the wound closure rate in full thickness as well as a diabetic wound model most probably due to its enhanced skin permeation. These findings demonstrate the therapeutic potential of rLMWP-EGF as a new topical wound healing drug and the site-specific conjugation of LMWP to peptides or proteins by genetic recombination as a useful method for preparing highly effective biomedicines.

[1]  S. Werner,et al.  Wound repair and regeneration , 1994, Nature.

[2]  B. Nordén,et al.  Membrane binding and translocation of cell-penetrating peptides. , 2004, Biochemistry.

[3]  Cheol Moon,et al.  Synthetic skin-permeable proteins enabling needleless immunization. , 2010, Angewandte Chemie.

[4]  E. Kobatake,et al.  Construction of multifunctional proteins for tissue engineering: epidermal growth factor with collagen binding and cell adhesive activities. , 2009, Journal of biotechnology.

[5]  T. Wakefield,et al.  Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote (III): Preliminary in vivo evaluation of efficacy and toxicity using a canine model , 2001, AAPS PharmSci.

[6]  S. Dowdy,et al.  Protein transduction domain delivery of therapeutic macromolecules. , 2011, Current opinion in biotechnology.

[7]  Vincent Falanga,et al.  Wound healing and its impairment in the diabetic foot , 2005, The Lancet.

[8]  V. Torchilin.  Intracellular delivery of protein and peptide therapeutics. , 2008, Drug discovery today. Technologies.

[9]  S. Futaki,et al.  Methodological and cellular aspects that govern the internalization mechanisms of arginine-rich cell-penetrating peptides. , 2008, Advanced drug delivery reviews.

[10]  H. Asada,et al.  Heparin-binding epidermal growth factor-like growth factor is an autocrine growth factor for human keratinocytes. , 1994, The Journal of biological chemistry.

[11]  J. Boateng,et al.  Wound healing dressings and drug delivery systems: a review. , 2008, Journal of pharmaceutical sciences.

[12]  K. Ulubayram,et al.  EGF containing gelatin-based wound dressings. , 2001, Biomaterials.

[13]  A. Ljubimov,et al.  High Glucose Suppresses Epidermal Growth Factor Receptor/Phosphatidylinositol 3-Kinase/Akt Signaling Pathway and Attenuates Corneal Epithelial Wound Healing , 2009, Diabetes.

[14]  S. W. Kim,et al.  Low molecular weight protamine as an efficient and nontoxic gene carrier: in vitro study , 2003, The journal of gene medicine.

[15]  E. Kobatake,et al.  Construction of epidermal growth factor fusion protein with cell adhesive activity. , 2006, Biomaterials.

[16]  Rebeccah L. Brown,et al.  PDGF and TGF-α Act Synergistically to Improve Wound Healing in the Genetically Diabetic Mouse , 1994 .

[17]  N. Renda,et al.  Epidermal growth factor‐containing wound closure enhances wound healing in non‐diabetic and diabetic rats , 2009, International wound journal.

[18]  Kam W Leong,et al.  In vivo wound healing of diabetic ulcers using electrospun nanofibers immobilized with human epidermal growth factor (EGF). , 2008, Biomaterials.

[19]  Shana O Kelley,et al.  Recent advances in the use of cell-penetrating peptides for medical and biological applications. , 2009, Advanced drug delivery reviews.

[20]  Han-Jung Lee,et al.  Transdermal delivery of proteins mediated by non‐covalently associated arginine‐rich intracellular delivery peptides , 2007, Experimental dermatology.

[21]  Stanley N. Cohen.  Alfred P. Sloan Jr. Award. The epidermal growth factor (EGF) , 1983, Cancer.

[22]  H. Natsume,et al.  Poly-L-Arginine Predominantly Increases the Paracellular Permeability of Hydrophilic Macromolecules Across Rabbit Nasal Epithelium in Vitro , 2003, Pharmaceutical Research.

[23]  Ulo Langel,et al.  Cell-penetrating peptides: mechanism and kinetics of cargo delivery. , 2005, Advanced drug delivery reviews.

[24]  J. Klarlund,et al.  Brief treatment with heparin-binding EGF-like growth factor, but not with EGF, is sufficient to accelerate epithelial wound healing. , 2011, Biochimica et biophysica acta.

[25]  Olivera Stojadinovic,et al.  PERSPECTIVE ARTICLE: Growth factors and cytokines in wound healing , 2008, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[26]  M. Morris,et al.  Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics , 2009, British journal of pharmacology.

[27]  S. Cohen.  The epidermal growth factor (EGF). , 1983, Cancer.

[28]  R. Patlolla,et al.  Translocation of cell penetrating peptide engrafted nanoparticles across skin layers. , 2010, Biomaterials.

[29]  Y. Miyachi,et al.  Tight junctions in the skin. , 2003, Journal of dermatological science.

[30]  C. Chung,et al.  The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine. , 2010, Biomaterials.

[31]  J. Rothbard,et al.  Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation , 2000, Nature Medicine.

[32]  Philip Bao,et al.  The role of vascular endothelial growth factor in wound healing. , 2009, The Journal of surgical research.

[33]  D. Schmaljohann,et al.  Epidermal growth factor therapy and wound healing--past, present and future perspectives. , 2008, The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland.

[34]  V. Yang,et al.  Reduced reactivity towards anti-protamine antibodies of a low molecular weight protamine analogue. , 2001, Thrombosis research.

[35]  Lokesh Joshi,et al.  Comparative Study of the Skin Penetration of Protein Transduction Domains and a Conjugated Peptide , 2005, Pharmaceutical Research.

[36]  A. Mandal,et al.  Application of a PDGF-containing novel gel for cutaneous wound healing. , 2010, Life sciences.

[37]  Steven F Dowdy,et al.  Cationic TAT peptide transduction domain enters cells by macropinocytosis. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[38]  M. Matsushita,et al.  Recent Advances in Protein Transduction Technology , 2010, Cell transplantation.

[39]  C. Chung,et al.  Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular protein delivery: in vitro and in vivo study , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[40]  Hoa Le Tuyet,et al.  The efficacy and safety of epidermal growth factor in treatment of diabetic foot ulcers: the preliminary results , 2009, International wound journal.

[41]  Y. Tabata,et al.  Controlled-release of epidermal growth factor from cationized gelatin hydrogel enhances corneal epithelial wound healing. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[42]  R. L. Smith,et al.  Relationships between nerves and myofibroblasts during cutaneous wound healing in the developing rat , 1999, Cell and Tissue Research.

[43]  G. Wong,et al.  Arginine‐rich cell‐penetrating peptides , 2010, FEBS letters.

[44]  H. Mitsui,et al.  Novel immunotherapeutic approaches to skin cancer treatments using protein transduction technology. , 2011, Journal of dermatological science.